secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001558370-23-016776
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma receives FDA approval for Cotempla XR-ODT site transfer, expects margin boost in 2024
--------------------------------------------------------------------------------

- FDA approved Cotempla XR-ODT Prior Approval Supplement (PAS) for manufacturing transfer to contract manufacturer.
- Adzenys XR-ODT received similar PAS approval in April 2023; both ADHD brands moving to contract production.
- Company expects enhanced ADHD product margins starting calendar 2024 after exiting Grand Prairie facility.
- Production ramp-up expected late 2023; Adzenys production already underway at contract manufacturer.
- CEO cites multi-year effort: bioequivalence studies, strong contract partners, and regulatory navigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023016776/0001558370-23-016776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023016776/aytu-20231025x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer